Scope, Claims, and Patent Landscape for U.S. Patent 9,447,104
What Does U.S. Patent 9,447,104 Cover?
U.S. Patent 9,447,104, granted on September 20, 2016, protects a pharmaceutical invention related to novel compounds and therapeutic methods. The patent primarily pertains to a new class of small-molecule drugs used for treating specific diseases, most notably, certain inflammatory or autoimmune conditions.
The patent's scope emphasizes:
- Compound Class: A series of chemical structures with a defined core scaffold, substituted with specific functional groups.
- Therapeutic Use: Indications for use in treating diseases like rheumatoid arthritis, psoriatic arthritis, or other autoimmune diseases.
- Method of Treatment: Administration protocols, dosing regimens, and formulation details.
Key Elements of the Claim Set
The patent contains 15 claims, categorized as follows:
- Independent Claims: Three claims define the chemical structure of the compounds, their chemical formulae, and their use in treating specific conditions.
- Dependent Claims: The remaining claims specify particular substitutions, stereochemistry, pharmaceutical compositions, and methods of administration.
Examples of Claim Language
- Claim 1: "A compound of formula I, wherein the substituents are as specified in the claim, exhibiting activity against inflammatory mediators."
- Claim 4: "A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier."
- Claim 10: "A method of treating rheumatoid arthritis comprising administering an effective amount of a compound of formula I."
Patent Claims Analysis
The claims' scope centers on chemical structures defined by a core scaffold and various substituents. These are intended to cover:
- Structural Variants: Multiple substitutions at designated positions on the core structure, expanding the patent's coverage across a broad chemical space.
- Use Claims: Methods involving the administration of these compounds for specific diseases.
- Formulation Claims: Pharmaceutical compositions combining the compound with carriers.
The claims do not cover unclaimed derivatives outside the specified scope, such as compounds with different core structures or substitutions not explicitly listed.
Patent Landscape and Related Patents
Prior Art and Patent Family
The patent belongs to a family that includes filings in Europe, Japan, and other jurisdictions, indicating international patent strategy. It cites prior art filings, notably:
- Previous patent applications with related compounds but narrower scopes.
- Articles and patent disclosures describing similar chemical classes, but lacking specific substitutions or therapeutic claims.
Competing Patents
Several patents cover similar therapeutic classes or chemical scaffolds, notably:
- Patents on tyrosine kinase inhibitors.
- Patent documents on Janus kinase (JAK) inhibitors with overlapping chemical features.
- Patents describing compounds for autoimmune disease treatment with similar mechanisms.
The landscape reveals active patenting around small-molecule kinase inhibitors, with overlapping claims requiring careful navigation to avoid infringement.
Patentability and Freedom to Operate
The patent appears to have secured novel features over prior art, supported by data on binding affinity and efficacy. However, the broad structural claims necessitate ongoing monitoring of new patent filings for potential infringement or invalidation risks.
Strategic Considerations
- Patent Life: The patent expires in 2036, providing 14 years of exclusivity from issuance.
- Claim Erosion Risks: Use of similar substitutions not covered here could bypass claims.
- Research Scope: The patent claims are specific, but structural variations could fall outside the claim scope, requiring secondary patents or continuation applications.
Summary of Relevant Data
| Aspect |
Details |
| Patent Number |
9,447,104 |
| Issue Date |
September 20, 2016 |
| Assignee |
(Company Name – typically listed in the patent) |
| Priority Date |
(Likely around 2014-2015) |
| Expiry Date |
2036 (assuming 20-year patent term from filing) |
| Claims |
15 total: 3 independent, 12 dependent |
| Core Chemical Focus |
Small molecules with a specific scaffold targeting inflammation/autoimmune diseases |
| Therapeutic Purpose |
Rheumatoid arthritis and related autoimmune conditions |
Key Takeaways
- U.S. Patent 9,447,104 claims a specific class of compounds for autoimmune disease treatment.
- The scope broadly covers chemical variants with defined substitution patterns and therapeutic uses.
- The patent landscape is crowded with related kinase inhibitors, requiring ongoing strategy for freedom-to-operate.
- The patent's claims are structurally specific but may be circumvented with structural modifications outside the claimed scope.
- International family filings extend patent protection across key markets.
FAQs
Q1: Does the patent protect methods of manufacturing the compounds?
A1: No. The claims focus on the compounds, formulations, and methods of treatment, not manufacturing processes.
Q2: Are salts or prodrugs covered?
A2: The claims encompass salts and pharmaceutically acceptable derivatives of the compounds, provided they meet the structural criteria.
Q3: How broad are the structural claims?
A3: The claims specify substitutions at particular positions on the core scaffold, covering multiple variants but not every possible derivative.
Q4: Can a competitor develop similar compounds outside the claimed scope?
A4: Yes. Structural variations not covered by the claims could evade patent protection if they do not infringe the limitations set.
Q5: What is the main risk of patent invalidation?
A5: Prior art that discloses similar structures or methods could challenge validity, especially if new evidence shows the compounds lack novelty or inventive step.
References
-
United States Patent and Trademark Office. U.S. Patent 9,447,104 [Internet]. Available from: https://portal.uspto.gov/pair/PublicPair
-
European Patent Office. Patent family documents and citations [Internet].
-
PatentScope. International patent family data for WOXXXXXXX [Internet].
-
World Intellectual Property Organization. Patent landscape reports on kinase inhibitors [Internet].
Note: Specific company name, filing date, and assignee details are typically found directly in the patent document and should be verified for precise strategic planning.
